Țară: Canada
Limbă: engleză
Sursă: Health Canada
ARIPIPRAZOLE
TEVA CANADA LIMITED
N05AX12
ARIPIPRAZOLE
15MG
TABLET
ARIPIPRAZOLE 15MG
ORAL
30/100
Prescription
ATYPICAL ANTIPSYCHOTICS
Active ingredient group (AIG) number: 0152514003; AHFS:
CANCELLED POST MARKET
2021-07-29
PRODUCT MONOGRAPH PR TEVA-ARIPIPRAZOLE Aripiprazole Tablets, USP 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg Antipsychotic agent Teva Canada Limited 30 Novopharm Court Toronto, Ontario Canada M1B 2K9 Date of Preparation: July 03, 2020 www.tevacanada.com Submission Control No: 240750 _ _ _TEVA-ARIPIPRAZOLE _ _ _ _Page 2 of 65 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................. 3 SUMMARY PRODUCT INFORMATION ................................................................................ 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS ........................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 14 DRUG INTERACTIONS ......................................................................................................... 31 DOSAGE AND ADMINISTRATION ..................................................................................... 35 OVERDOSAGE ........................................................................................................................ 37 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 38 STORAGE AND STABILITY ................................................................................................. 40 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................... 40 PART II: SCIENTIFIC INFORMATION ................................................................................... 42 PHARMACEUTICAL INFORMATION ................................................................................. 42 CLINICAL TRIALS .................................................. Citiți documentul complet